SRNE - Brazil Healthcare Regulator Authorizes Sorrento Therapeutics' Phase 2 Trial for Coronavirus Drug Candidate
Abivertinib, one of Sorrento Therapeutics ' (NASDAQ: SRNE) COVID-19 drug candidates, will be entering phase 2 testing in Brazil. This follows approval granted on Wednesday by the National Health Surveillance Agency (ANVISA), the country's healthcare regulator, which has cleared the U.S. company to advance the drug's development in the sprawling South American nation.
Abivertinib was originally designed to treat cancer; Sorrento believes it can limit the overactive immune systems seen in some COVID-19 patients.
In July, the drug was cleared for phase 2 testing in the U.S., but the Brazil study will have several differences. Among other distinctions, it will involve patients with mild, moderate, or severe forms of the illness; participants in the American trial are limited to severe COVID-19 cases. In Brazil, any hospitalized patient will be eligible; patients in the U.S. study must be in the intensive care unit and nonventilated.
For further details see:
Brazil Healthcare Regulator Authorizes Sorrento Therapeutics' Phase 2 Trial for Coronavirus Drug Candidate